Asenapine transdermal system for schizophrenia

Dr. Citrome is Clinical Professor of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, New York. He is Current Psychiatry’s Section Editor, Psychopharmacology.

Disclosure
No writing assistance or external financial support was utilized in the production of this article. Dr. Citrome has been a consultant for Noven Pharmaceuticals since 2011 on the development of antipsychotic transdermal formulations, and on the development of the asenapine transdermal system since 2014. In the past 5 years Dr. Citrome has engaged in collaborative research with, or received consulting or speaking fees from, AbbVie, Acadia, Alexza, Alkermes, Allergan, Astellas, AstraZeneca, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Bristol-Myers Squibb, Cadent Therapeutics, Eisai, Eli Lilly, Forum, Genentech, Impel, Indivior, Intra-Cellular Therapies, Janssen, Jazz, Karuna, Lundbeck, Luye, Meiji, Merck, Medivation, Mylan, Neurocrine, Novartis, Noven, Osmotica, Otsuka, Pfizer, Reckitt Benckiser, Relmada, Reviva, Sage, Shire, Sunovion, Takeda, Teva, Valeant, and Vanda.